Compass Therapeutics Q2 net loss $13.1M; CTX-009 BTC trial enrollment completed, top-line data Q1 2025

Compass Therapeutics, Inc.

Net loss of $13.1M ($0.10 per share) for Q2 2024 vs $11.3M loss in Q2 2023.
Cash and marketable securities $146M as of June 30, 2024; cash runway into Q1 2027.
Completed enrollment (n=150) in COMPANION-002 Phase 2/3 trial of CTX-009 in BTC; top-line data expected Q1 2025.
Stage 1 of COMPANION-003 in CRC showed ORR 5%, median PFS 3.9 months, median OS 10.2 months; designing second-line DLL4+ study.
Discontinuing CTX-471 + KEYTRUDA combo due to cytokine suppression; planning Phase 2 monotherapy with new biomarker.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.